Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 21, 2015, 38 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $259.00 to $5,226,379.88.

Highlighted Stocks Traded by Insiders:

Hemispherx Biopharma (HEB) - FREE Research Report

Equels Thomas K., who is CFO, Vice Chairman, Secretary at Hemispherx Biopharma, bought 100,000 shares at $0.24 on April 21, 2015. Following this transaction, the CFO, Vice Chairman, Secretary owned 1.2 million shares meaning that the stake was boosted by 9.05% with the 100,000-share transaction.

The shares most recently traded at $0.25, up $0.01, or 4.36% since the insider transaction. Historical insider transactions for Hemispherx Biopharma go as follows:

  • 4-Week # shares bought: 200,000
  • 12-Week # shares bought: 200,000
  • 24-Week # shares bought: 200,000

The average volume for Hemispherx Biopharma has been 1.9 million shares per day over the past 30 days. Hemispherx Biopharma has a market cap of $50.8 million and is part of the health care sector and drugs industry. Shares are down 5.6% year-to-date as of the close of trading on Tuesday.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. Currently, there are no analysts who rate Hemispherx Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HEB - FREE

TheStreet Quant Ratings

rates Hemispherx Biopharma as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Hemispherx Biopharma Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Morgan Stanley (MS) - FREE Research Report

Grossman Eric F, who is Chief Legal Officer at Morgan Stanley, sold 34,481 shares at $37.10 on April 21, 2015. Following this transaction, the Chief Legal Officer owned 124,646 shares meaning that the stake was reduced by 21.67% with the 34,481-share transaction.

The shares most recently traded at $36.66, down $0.44, or 1.21% since the insider transaction. Historical insider transactions for Morgan Stanley go as follows:

  • 4-Week # shares sold: 25,000
  • 12-Week # shares sold: 25,000
  • 24-Week # shares sold: 25,000

The average volume for Morgan Stanley has been 9.9 million shares per day over the past 30 days. Morgan Stanley has a market cap of $72.9 billion and is part of the financial sector and financial services industry. Shares are down 5.28% year-to-date as of the close of trading on Tuesday.

Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals worldwide. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 17.7. Currently, there are 6 analysts who rate Morgan Stanley a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MS - FREE

TheStreet Quant Ratings

rates Morgan Stanley as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Morgan Stanley Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Imperva (IMPV) - FREE Research Report

Kraynak Mark E., who is Chief Product Officer at Imperva, sold 3,000 shares at $47.53 on April 21, 2015. Following this transaction, the Chief Product Officer owned 12,160 shares meaning that the stake was reduced by 19.79% with the 3,000-share transaction.

The shares most recently traded at $47.79, up $0.26, or 0.54% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 18,313

The average volume for Imperva has been 474,900 shares per day over the past 30 days. Imperva has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are down 1.76% year-to-date as of the close of trading on Tuesday.

Imperva, Inc. develops, markets, sells, services, and supports cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. It operates in two segments, Imperva and Incapsula. Currently, there are 10 analysts who rate Imperva a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings

rates Imperva as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Imperva Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null